These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 1684803

  • 1. CV 205-502 treatment of macroprolactinomas.
    Crottaz B, Uske A, Reymond MJ, Rey F, Siegel RA, Brownell J, Gomez F.
    J Endocrinol Invest; 1991 Oct; 14(9):757-62. PubMed ID: 1684803
    [Abstract] [Full Text] [Related]

  • 2. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
    van der Lely AJ, Brownell J, Lamberts SW.
    J Clin Endocrinol Metab; 1991 May; 72(5):1136-41. PubMed ID: 1673685
    [Abstract] [Full Text] [Related]

  • 3. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [Abstract] [Full Text] [Related]

  • 4. Long-term treatment of macroprolactinomas with CV 205-502.
    Kvistborg A, Halse J, Bakke S, Bjøro T, Hansen E, Djøseland O, Brownell J, Jervell J.
    Acta Endocrinol (Copenh); 1993 Apr; 128(4):301-7. PubMed ID: 8098891
    [Abstract] [Full Text] [Related]

  • 5. Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine.
    Merola B, Sarnacchiaro F, Colao A, Di Somma C, Di Sarno A, Ferone D, Selleri A, Landi ML, Schettini G, Nappi C.
    Gynecol Endocrinol; 1994 Sep; 8(3):175-81. PubMed ID: 7847102
    [Abstract] [Full Text] [Related]

  • 6. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
    Colao A, Merola B, Sarnacchiaro F, Di Sarno A, Landi ML, Marzullo P, Cerbone G, Ferone D, Lombardi G.
    Horm Res; 1995 Sep; 44(5):222-8. PubMed ID: 8582715
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
    Brue T, Pellegrini I, Gunz G, Morange I, Dewailly D, Brownell J, Enjalbert A, Jaquet P.
    J Clin Endocrinol Metab; 1992 Mar; 74(3):577-84. PubMed ID: 1346788
    [Abstract] [Full Text] [Related]

  • 9. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.
    Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, Facciolli G, Lombardi G.
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2777-80. PubMed ID: 9709946
    [Abstract] [Full Text] [Related]

  • 10. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502.
    Barnett PS, Palazidou E, Miell JP, Coskeran PB, Butler J, Dawson JM, Maccabe J, McGregor AM.
    Q J Med; 1991 Nov; 81(295):891-906. PubMed ID: 1687293
    [Abstract] [Full Text] [Related]

  • 11. [Treatment of prolactinoma with a new dopamine agonist].
    Svoboda T, Luger A, Knosp E, Geyer G.
    Dtsch Med Wochenschr; 1991 Aug 16; 116(33):1224-7. PubMed ID: 1678695
    [Abstract] [Full Text] [Related]

  • 12. CV 205-502 in the treatment of tumoral and non-tumoral hyperprolactinemic states.
    Merola B, Sarnacchiaro F, Colao A, Di Somma C, Di Sarno A, Landi ML, Marzullo P, Panza N, Battista C, Lombardi G.
    Biomed Pharmacother; 1994 Aug 16; 48(3-4):167-74. PubMed ID: 7993981
    [Abstract] [Full Text] [Related]

  • 13. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.
    Duranteau L, Chanson P, Lavoinne A, Horlait S, Lubetzki J, Kuhn JM.
    Clin Endocrinol (Oxf); 1991 Jan 16; 34(1):25-9. PubMed ID: 1672268
    [Abstract] [Full Text] [Related]

  • 14. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 1997 Mar 16; 82(3):876-83. PubMed ID: 9062500
    [Abstract] [Full Text] [Related]

  • 15. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.
    Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P.
    Eur J Endocrinol; 1996 Oct 16; 135(4):413-20. PubMed ID: 8921822
    [Abstract] [Full Text] [Related]

  • 16. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
    Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G.
    J Clin Endocrinol Metab; 1997 Nov 16; 82(11):3574-9. PubMed ID: 9360509
    [Abstract] [Full Text] [Related]

  • 17. Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV 205-502.
    van't Verlaat JW, Croughs RJ, Brownell J.
    Clin Endocrinol (Oxf); 1990 Nov 16; 33(5):619-24. PubMed ID: 1979262
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of quinagolide in resistance to dopamine agonists: results of a multicenter study. Club de l'Hypophyse.
    Rohmer V, Freneau E, Morange I, Simonetta C.
    Ann Endocrinol (Paris); 2000 Nov 16; 61(5):411-7. PubMed ID: 11084391
    [Abstract] [Full Text] [Related]

  • 19. Prolactinomas and resistance to dopamine agonists.
    Brue T, Pellegrini I, Priou A, Morange I, Jaquet P.
    Horm Res; 1992 Nov 16; 38(1-2):84-9. PubMed ID: 1306523
    [Abstract] [Full Text] [Related]

  • 20. Effects of a new prolactin inhibitor, CV 205-502, in the treatment of human macroprolactinomas.
    Khalfallah Y, Claustrat B, Grochowicki M, Flocard F, Horlait S, Serusclat P, Sassolas G.
    J Clin Endocrinol Metab; 1990 Aug 16; 71(2):354-9. PubMed ID: 1974262
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.